A
Alcista
Alcista · 25%CLGN
$10.06
Precio del escenario
$3.970
+0.030 (+0.76%)Al cierre
Loading chart…
- Máximo
- 4.189
- Apertura
- 4.180
- Precio medio ponderado por volumen
- 4.00
- Volumen
- 29.22K
- Capitalización
- 57.27M
- Mínimo
- 3.850
- Importe
- 116.96K
- EV/EBITDA, TTM
- -0.06
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Análisis de IA of Collplant Biotechnologies Ltd (CLGN)
MantenerCollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
Métricas de valoración
El PER previsto actual de Collplant Biotechnologies Ltd (CLGN) es 80.00, frente a su media de 5 años de 16.78.
Escenarios de precio de Alphio AI para CLGN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.510-09PRnewswireCollPlant Secures Private Placement to Accelerate R&D
3.510-06PRnewswireCollPlant Advances Photonic Computing Strategy
3.510-06NewsfilterCollPlant Advances Photonic Computing Strategy Through LightSolver's IP Growth
8.509-30PRnewswireCollPlant Expands into Photonic Computing with LightSolver Acquisition
- 8.509-30Newsfilter
CollPlant Acquires LightSolver to Expand Technology Portfolio
Preguntas frecuentes sobre CLGN, respondidas por Alphio AI
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).
CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.